Comment on

• Effects of extended-release niacin with laropiprant in high-risk patients.

  HPS2-THRIVE Collaborative Group; Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, Wallendszus K, Craig M, Jiang L, Collins R, Armitage J. HPS2-THRIVE Collaborative Group, et al. N Engl J Med. 2014 Jul 17;371(3):203-12. doi: 10.1056/NEJMoa1300955. N Engl J Med. 2014. PMID: 25014686 Clinical Trial.
• Niacin for reduction of cardiovascular risk.

  Rembold CM. Rembold CM. N Engl J Med. 2014 Nov 13;371(20):1940-1. doi: 10.1056/NEJMc1411240. N Engl J Med. 2014. PMID: 25390749 No abstract available.
• Niacin for reduction of cardiovascular risk.

  Meneses F. Meneses F. N Engl J Med. 2014 Nov 13;371(20):1941. doi: 10.1056/NEJMc1411240. N Engl J Med. 2014. PMID: 25390750 No abstract available.
• Niacin for reduction of cardiovascular risk.

  Hu M, Tomlinson B. Hu M, et al. N Engl J Med. 2014 Nov 13;371(20):1941-2. doi: 10.1056/NEJMc1411240. N Engl J Med. 2014. PMID: 25390751 No abstract available.
• Niacin for reduction of cardiovascular risk.

  van den Oever IA, Nurmohamed MT, Lems WF. van den Oever IA, et al. N Engl J Med. 2014 Nov 13;371(20):1942. doi: 10.1056/NEJMc1411240. N Engl J Med. 2014. PMID: 25390752 No abstract available.
• Niacin for reduction of cardiovascular risk.

  Santos-Gallego CG, Badimon J. Santos-Gallego CG, et al. N Engl J Med. 2014 Nov 13;371(20):1943. doi: 10.1056/NEJMc1411240. N Engl J Med. 2014. PMID: 25390753 No abstract available.
• Niacin for reduction of cardiovascular risk.

  Mayer L. Mayer L. N Engl J Med. 2014 Nov 13;371(20):1943. doi: 10.1056/NEJMc1411240. N Engl J Med. 2014. PMID: 25390754 No abstract available.